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Beta defensins comprise a family of cationic, cysteine-rich antimicrobial peptides, predominantly expressed
at epithelial surfaces. Previously we identified a unique five-cysteine defensin-related peptide (Defr1) that,
when synthesized, is a mixture of dimeric isoforms and exhibits potent antimicrobial activity against Esche-
richia coli and Pseudomonas aeruginosa. Here we report that Defr1 displays antimicrobial activity against an
extended panel of multidrug-resistant nosocomial pathogens for which antimicrobial treatment is limited or
nonexistent. Defr1 fractions were collected by high-pressure liquid chromatography and analyzed by gel
electrophoresis and mass spectrometry. Antimicrobial activity was initially investigated with the type strain
Pseudomonas aeruginosa PAO1. All fractions tested displayed equivalent, potent antimicrobial activity levels
comparable with that of the unfractionated Defr1. However, use of an oxidized, monomeric six-cysteine
analogue (Defr1 Y5C), or of reduced Defr1, gave diminished antimicrobial activity. These results suggest that
the covalent dimer structure of Defr1 is crucial to antimicrobial activity; this hypothesis was confirmed by
investigation of a synthetic one-cysteine variant (Defr1-1cys). This gave an activity profile similar to that of
synthetic Defr1 but only in an oxidized, dimeric form. Thus, we have shown that covalent, dimeric molecules
based on the Defr1 -defensin sequence demonstrate antimicrobial activity even in the absence of the canonical
cysteine motif.
The emergence of multidrug-resistant bacterial pathogens
continues to reduce the antibiotic options available to clini-
cians in the treatment of serious nosocomial infections. This
threat particularly applies to pathogens responsible for infec-
tions in intensive care units; these include methicillin-resistant
Staphylococcus aureus, Pseudomonas aeruginosa, Enterococcus
faecalis, and Acinetobacter baumannii (15). The increased prev-
alence of resistant P. aeruginosa in cystic fibrosis lung infec-
tions and high-level innate resistance in other opportunistic
pathogens, including the Burkholderia cepacia complex,
Stenotrophomonas maltophilia, Candida albicans, and Ralstonia
species, are also causes for concern (1). Clearly, there is a need
for novel antimicrobial agents.
-Defensins are cysteine-rich, cationic peptides displaying
important roles within the mammalian innate immune system
(6). In vitro and in vivo studies have confirmed that defensins
have potent broad-spectrum bactericidal activity and suggest
that bacterial resistance may have coevolved with, and influ-
enced the diversity of, antimicrobial peptides (2, 8, 11). In
addition, -defensins have been shown to act upon T lympho-
cytes and immature dendritic cells playing key roles in the
adaptive immune response (19). -Defensins produced as
propeptides are processed to a mature secreted peptide, which
contains six canonical cysteine residues (cys1-cys5, cys2-cys4,
cys3-cys6) with specific spacing and intramolecular disulfide
connectivity (18). These are distinct from the disulfide connec-
tivities displayed by the similar -defensins (17). The mature
-defensins are 30 to 45 amino acids in length and are amphi-
pathic, containing discrete cationic and hydrophobic areas.
A mechanism for defensin binding and disruption of bacte-
rial membranes is the subject of intensive study (12). Active
peptides have been shown to display an appropriate balance of
hydrophobicity and net positive charge (5). The conserved
disulfide bridges impose a structural core composed of -sheets,
and nonconserved residues on the surface are subject to selec-
tive pressure against rapidly evolving bacteria (10, 14). In di-
rect contrast to the perceived structure-function relation-
ship(s), however, it has been reported that antimicrobial
activity is independent of intramolecular disulfide bridging
(18).
Recently we described a murine -defensin gene present in
C57BL/6 mice that encoded a peptide with only five cysteine
residues (Table 1) (9). This peptide (Defr1) displays a tyrosine
in place of the first cysteine and yet still retains potent antimi-
crobial activity against gram-positive and gram-negative organ-
isms. The gene is a variant allele of Defb8 which encodes six
cysteines and is present in all the other inbred murine strains
we have tested. A synthetic analogue of Defr1 (Defr1 Y5C) in
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which the tyrosine is restored to a cysteine exists as a nonco-
valent homodimer formed by monomers with -defensin con-
nectivity but displays poor antimicrobial activity (3). In con-
trast, we found that synthetic Defr1 was a mixture of isoforms
with variable disulfide connectivities but that each isoform
contained a single intermolecular S-S bond. We found that the
antimicrobial activity was influenced by the covalent dimeric
structure imposed by this novel defensin motif (3).
In this study we evaluated the antimicrobial activity of Defr1
against a panel of bacteria and fungi selected to represent
important multidrug-resistant nosocomial pathogens. Reverse-
phase high-pressure liquid chromatography (HPLC) was per-
formed using the synthetic preparation of Defr1, and 14 frac-
tions were collected for examination of the activity of the
specific isoforms of the peptide. Additionally, sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and mass spectrom-
etry were used to examine the structures of the peptides within
these fractions, all of which possess similar antimicrobial prop-
erties. Reduced Defr1 has poor antimicrobial activity, implying
that its disulfide-linked, dimeric structure is important for ac-
tivity (3); therefore, we synthesized a peptide with only one
cysteine that formed a dimer of defined structure. This one-
cysteine variant (Defr1-1cys) in an oxidized, dimeric form gave
an activity profile similar to that of synthetic Defr1; however,
this activity was greatly reduced after the single S-S bond was
broken using dithiothreitol (DTT). Thus, this synthetic peptide
based on the Defr1 -defensin sequence shows potent antimi-
crobial activity in the absence of the characteristic -defensin
cysteine motif but only in an oxidized, disulfide-linked, cova-
lent dimer form.
MATERIALS AND METHODS
Materials. Defr1 Y5C, Defr1, and Defr1-1cys were chemically synthesized by
the standard solid-phase methodology (CSS Albachem Ltd.) and were refolded
and oxidized in air as described previously (3). Polymyxin B sulfate was pur-
chased from Sigma.
Antimicrobial assays. Test organisms were grown to midlogarithmic phase in
Iso-Sensitest broth (Oxoid) growth media and then diluted to 1  106 to 5  106
CFU/ml in 10 mM potassium phosphate containing 1% (vol/vol) Iso-Sensitest
broth, pH 7.4. Different concentrations of test peptide were incubated in 100 l
of cells (1  105 to 5  105 CFU) at 37°C for 3 h. Reduction of the peptides,
where performed, was done by adding 10 mM DTT and incubating at room
temperature overnight. The oxidation state of each peptide was determined by
mass spectrometry. Serial dilutions (10-fold) of the incubation mixture were
spread on Iso-Sensitest plates and incubated at 37°C, and the CFU levels were
determined the following day. The minimum bactericidal concentration (MBC)
is the concentration of peptide at which we observed 99.99% killing of the
initial inoculum. All assays were performed in triplicate on three independent
occasions. The MBC was obtained by taking the mean of all results, and exper-
imental errors were within one doubling dilution.
The effect of salt on antimicrobial activity was tested by incubating 100 l of
1  105 CFU of P. aeruginosa PAO1 in 10 mM potassium phosphate–1%
(vol/vol) Iso-Sensitest (pH 7.4), which contained various concentrations of NaCl
(0 to 200 mM). The bacteria were then challenged with peptide at various
concentrations (doubling dilutions from 0 to 150 g/ml), and the MBC for each
concentration was determined.
Defr1 fractionation-HPLC. Preparative reverse-phase HPLC for this study was
performed by CSS Albachem Ltd. The peptide was fractionated with a gradient
of 20% to 30% acetonitrile over 60 min on a Jupiter C5 Semi-Prep column
(Phenomenex, Macclesfield, United Kingdom) (250 by 10 mm) at a flow rate of
5 ml/min. Fractions (5 ml) (i.e., 1 min) were collected throughout the region of
interest in order to sample across the chromatographic peak (data not shown).
The fractions were lyophilized, weighed, and resuspended in water to give solu-
tions of 1 mg/ml.
Gel electrophoresis. Electrophoresis of Defr1, Defr1 fractions, and Defr1-1cys
was performed under reducing and native, nonreducing conditions. Peptide (2.5
g) was dissolved in 2.5 l of 0.01% acetic acid–5 l of 2 sample buffer (Novex
Tricine-sodium dodecyl sulfate sample buffer LC1676). Reduction of samples
was performed by adding 10 mM of NuPAGE sample-reducing agent (Invitrogen
NP0004) and incubating at room temperature for 1 h. The entire sample was
loaded on a 16% Tricine gel (Invitrogen). The gel was fixed and stained with
Coomassie blue stain.
Mass spectrometry. All data were taken on a Q-ToF mass spectrometer
(Micromass) fitted with a nanoelectrospray source. Nanospray tips were pulled
using a Sutter P97 tip puller with a voltage applied through a short length of
platinum wire. Samples were prepared at 10 M in 1:1 MeOH/H2O–0.1% formic
acid.
Analytical HPLC data. Peptides were separated on a Phenomenex Jupiter C5
column (250 by 2 mm) with a 20% to 30% acetonitrile gradient over 60 min at
0.2 ml/min by use of a Waters 2795 LC system attached to a Micromass Platform
II mass spectrometer. Synthetic Defr1 was prepared at 20 M in 1:1 MeOH/
H2O, with a total injection of 40 l.
RESULTS
Antimicrobial activity of Defr1 and Defr1 Y5C against a
panel of pathogens. We have extended our previous study
where we investigated the antimicrobial activity and specificity
of Defr1 (3), and here we used sensitive reference strains of
Escherichia coli, P. aeruginosa, and Bordetella bronchiseptica
and an extended panel which represented multidrug-resistant
isolates of major nosocomial pathogens (Table 2). These in-
cluded four nonclonal multidrug-resistant isolates of P. aerugi-
nosa responsible for epidemic outbreaks of respiratory in-
fection in individuals with cystic fibrosis. Polymyxin B was
also included as a reference cationic peptide presently in
clinical use.
Synthetic Defr1 showed bactericidal activity against the ma-
jority of bacterial pathogens investigated and also antifungal
activity against C. albicans (Table 2). MBCs were generally less
than 10 g/ml for both gram-positive and gram-negative bac-
teria. In separate experiments, bactericidal activity of Defr1
was shown to occur rapidly, within 30 min of exposure (data
not shown). Polymyxin B showed good activity against P.
aeruginosa, E. coli, and B. bronchiseptica but poor activity
against other members of the strain panel. Only the B. cepacia
and B. cenocepacia isolates showed high-level resistance to
Defr1 (MBC  100 g/ml), a result which is in agreement with
TABLE 1. Properties of Defr1 and related peptidesa
Peptide Sequence Charge G (kcal mol1)
Defr1 DPVTYIRNGGICQYRCIGLRHKIGTCGSPFKCCK 6 (12) 1.92 (3.84)
Defr1 Y5C DPVTCIRNGGICQYRCIGLRHKIGTCGSPFKCCK 6 (12) 3.13 (6.26)
Defr1-1cys DPVTYIRNGGIAQYRAIGLRHKIGTAGSPFKCAK 6 (12) 3.56 (7.12)
a Amino acid sequence, charge, and hydrophobicity (G) values as calculated by Wimley and White (16) are given for Defr1, Defr1Y5C, and Defr1-1cys. Values are
for the monomeric forms of the peptides, with values for the dimeric forms in brackets. Boldface letters indicate the position of cysteine residues in a canonical six
cysteine -defensin motif.
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the characteristic resistance of these bacteria to conventional
antibiotics and AMPs (13). We previously reported the bacte-
ricidal activity of Defr1 against B. cenocepacia J2315, with
which, even at 50 g/ml of peptide, only 40% killing of the
bacterial inoculum was achieved (9). Importantly, in this new
study the antimicrobial activities of Defr1 against both mul-
tiresistant and susceptible pathogens were similar, and in all
cases, the activity of 5-cysteine Defr1 was greater than that of
the 6-cysteine analogue (Defr1 Y5C). Indeed, when tested
against P. aeruginosa, E. coli, S. aureus, methicillin-resistant
Staphylococcus aureus, and S. maltophilia, the Defr1 disulfide
dimer exhibited 10-fold-greater bactericidal activity.
In order to determine whether any particular fraction of the
Defr1 preparation contained a more active isoform, we resyn-
thesized Defr1 and attempted to resolve the isoforms by sep-
aration using reverse-phase HPLC and a shallow elution gra-
dient. We collected 14 5-ml fractions, and each was lyophilized,
analyzed by native gel electrophoresis on a 16% Tricine gel
(Fig. 1 upper panel), and subsequently tested for antimicrobial
activity against the P. aeruginosa type strain PAO1.
Each fraction apparently displayed a different band intensity
of between 	5 to 13 kDa on the 16% Tricine gel, perhaps due
to the presence of different isoforms within the sample, a
phenomenon we had observed previously (3). Fractions 2, 9,
and 13 were selected due to their noticeably different mobili-
ties and were subjected to electrospray ionization mass spec-
trometry analysis (Fig. 1, lower panel) and in the reduced form
after treatment with DTT (data not shown). The ion series
results were essentially identical for all fractions, with each
peptide producing a series of ions of similar charges and in-
tensities (between [M  7H]7 and [M  10H]10). The de-
convoluted mass measured for each fraction is consistent with
the theoretical mass (7,567.0 Da), suggesting that each con-
tained a fully oxidized Defr1. This mass analysis revealed that
despite apparent mobility differences on the native, Tricine gel,
the three fractions chosen were all dimeric forms of the pep-
TABLE 2. Antimicrobial activity of Defr1 against a spectrum of gram-positive and gram-negative organisms and a fungus
Organism and straina Description ororigin
MBC (g/ml)b
Pol Defr1 Defr1 Y5C
Defr1-1cys
Oxidized Reduced
Gram-negative bacteria
P. aeruginosa
PAO1 Reference strain 0.5 6 50 6 50
C3425 Manchester 1 6 50
H183 Liverpool 1 6 100
C4269 Brisbane 1 6 100
C3781 Melbourne 0.5 6 100
E. coli
ATCC 25922 Reference strain 0.25 8 100 12 50
B. cepacia
ATCC 25416 Type strain 512 100 100
B. cenocepacia
ATCC BAA-245 Type strain 512 100 100 100 100
S. maltophilia
C1980 Clinical isolate 32 12.5 100
C3625 Clinical isolate 32 6 100
C3626 Clinical isolate 32 3 100
C3627 Clinical isolate 64 6 100
B. bronchiseptica
J3083 Reference strain 0.12 6 100
R. pickettii
R4050/C3079 Reference strain 512 3 100
R. eutropha
ATCC 17697 Reference strain 128 3 100
A. baumannii
ATCC 19606 Type strain 1 3 12.5 6 50
Gram-positive bacteria
E. faecalis ATCC 700802 Reference strain 256 6 100 12 50
S. aureus ATCC 25923 Reference strain 256 10 100 12 50
S. aureus J2918-MRSAc Clinical isolate 64 6 100
Fungus
C. albicans J2922 Clinical isolate 512 3 25
a Resistance phenotypes of clinical isolates for ciprofloxacin (Cip), meropenem (Mer), tobramycin (Tob) colistin (Col), and methicillin (Met): strain C3425, Mer
resistant 
Mer-R, Col-R; H183, Tob-R; C4269, Tob-R; C3781, Mer-R, Tob-R; C1980, Cip-R, Mer-R, Tob-R; C3625, Cip-R, Mer-R, Col-R; C3626, Cip-R, Mer-R;
C3627, Mer-R, Tob-R; J2918, Cip-R, Met-R.
b Values represent the MBCs for oxidized Defr1, Defr1 Y5C, and polymyxin (Pol) as a control. MBC data for Defr1 and Y5C against PAO1, E. coli ATCC 25922,
S. aureus ATCC 25923, E. faecalis ATCC 292126, and C. albicans J2922 have been previously reported (3) and are repeated here as comparators.
c MRSA, methicillin-resistant Staphylococcus aureus.
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tide, with masses which corresponded to a state in which all of
their cysteines are oxidized, i.e., representing a fully disulfide-
bridged, dimeric peptide, where the dimer is formed via an
intermolecular disulfide bridge. All of the fractions displayed
LC profiles similar to that of the unfractionated parental Defr1
(data not shown); combined with the heterogeneity observed in
the gel electrophoresis profile across the elution gradient, this
suggests that the Defr1 mixture is complex and difficult to
resolve.
Each of the 14 fractions in Fig. 1 was tested for antimicrobial
activity, and each had an MBC of 6 g/ml, which is the same as
that of the parental preparation of Defr1. Treatment of the
peptide fractions with excess DTT resulted in the loss of the
dimer structure (confirmed by mass spectrometry; data not
shown) and a corresponding marked decrease in antimicrobial
activity to an MBC greater than 50 g/ml (Fig. 2 and 3).
Antimicrobial activity of a single-cysteine dimer. In an at-
tempt to confirm the relationship between covalent dimeriza-
tion and potent antimicrobial activity, a one-cysteine variant
(Defr1-1cys) was synthesized (Table 1). The penultimate cys-
teine was retained, as this was considered to be the cysteine
without a partner in the five-cysteine peptide Defr1 when ca-
nonical -defensin disulfide connectivities (C1-C5, C2-C4, C3-
C6) were assumed. The other cysteines in the peptide were
replaced with an alanine. Following exposure to air, Defr1-1cys
spontaneously forms a disulfide-bridged dimer with a mass of
7,318.4 Da (theoretical mass, 7,318.54 Da) as opposed to the
theoretical value of 7,320.5 Da for a non-cysteine-bridged non-
covalent dimer (data not shown). Defr1-1cys was tested for
antimicrobial activity against a selection of gram-positive and
gram-negative organisms (Table 2).
Defr1-1cys displays antimicrobial activity identical to that of
Defr1 against the panel of organisms tested. Only the gram-
negative strain B. cenocepacia J2315 was not killed at a low
MBC. Again upon reduction in the presence of DTT, the
dimer structure of Defr1-1cys was lost (Fig. 3) and the antimi-
crobial activity was diminished (Table 2).
The salt sensitivity of Defr1 is unusual, as this cationic pep-
tide’s antimicrobial action against P. aeruginosa is largely in-
sensitive to salt concentration levels. The salt sensitivity of
Defr1-1cys was also tested and was found to be equivalent to
that previously reported for Defr1 (3, 9). In NaCl-free condi-
FIG. 1. Analysis of fractions from reverse-phase HPLC separation of Defr1. Upper panel: native gel electrophoresis of Defr1 fractions in 16%
Tricine gels. The 5-ml fractions taken from the HPLC preparation of Defr1 were subjected to electrophoresis in nondenaturing gels. Lower panel:
electrospray ionization–mass-spectrum ion envelopes of fractions 2, 9, and 13 from the Defr1 HPLC. Spectrum a corresponds to fraction 2,
spectrum b corresponds to fraction 9, and spectrum c corresponds to fraction 13. The mass of the dominant species (indicated above each x axis
by an “A” followed by a numeral) is given for each spectrum; the mass values determined agree with the mass expected for the fully disulfide
bridged form of the ion in each case, with an accuracy of 1 Da. Peaks are labeled “An,” with the indicated numbers corresponding to the
individual charge states given by the molecular ions of A in the form (M  nH)n. Some small impurity peaks are noted. Similar spectra were
obtained for all fractions despite their having somewhat dissimilar gel mobilities.
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tions, the MBC was 6 g/ml. At 50 and 100 mM NaCl, 25 g/ml
of Defr1-1cys peptide effectively killed the 105 bacteria in the
MBC assay. At 150 mM and 200 mM NaCl, 50 g/ml of the
single cysteine peptide was required to kill the bacteria.
DISCUSSION
Defr1 is a murine beta defensin-like peptide expressed in the
airways, testis, and heart (9). This peptide lacks the first cys-
teine of the characteristic six-cysteine canonical motif. Analy-
ses of functional characteristics show this peptide to possess
antimicrobial activity against both gram-positive and gram-
negative organisms. The precise mechanism of action of anti-
microbial peptides is unclear but is thought to include electro-
static binding and disruption of bacterial cell membranes (12).
Defr1 forms a covalent dimeric structure using an intermolec-
ular disulfide bond and to date has been considered a unique
example within the defensin family (3, 9).
Defr1 is shown here to express potent antimicrobial activity
against a range of bacterial pathogens, including multidrug-
resistant nosocomial isolates; the exceptions are B. cepacia and
B. cenocepacia, which are characteristically resistant to antimi-
crobial peptides. In comparison, Defr1 Y5C, the peptide ana-
logue which retains the canonical -defensin connectivity
(cys1-cys5, cys2-cys4, cys3-cys6) and has been shown previously
by mass spectrometry analysis not to be a covalent dimer (3),
displays poor antimicrobial activity against the same panel of
organisms.
Synthetic Defr1 has been shown previously to exhibit various
disulfide connectivities (3). In an attempt to identify active
fractions, samples from a reverse-phase HPLC column were
collected, analyzed by native gel electrophoresis, and investi-
gated for antimicrobial activity. All fractions displayed visibly
different but similar band intensities on a Tricine gel (Fig. 1,
upper panel) and yet retained antimicrobial activities equiva-
lent to that seen with the unfractionated Defr1. Further anal-
ysis of fractions 2, 9, and 13 was conducted due to their no-
ticeable mobility differences on gel electrophoresis. Analysis by
mass spectrometry showed that all fractions possessed a dom-
inant molecular species which had a mass corresponding to a
covalently bound dimeric form of the Defr1 peptide (Fig. 1,
lower panel), although some small additional peaks in each
fraction were present due to synthetic impurities and nonspe-
cific adducts formed in the electrospray process. LC analyses of
the synthetic Defr1 and of resolved fractions from it resulted in
chromatograms which exhibit very close correlation (data not
shown). Their chromatographic profiles also resemble that ob-
served with our first batch of synthetic Defr1 (data not shown).
Upon reduction of both the fractions and the parental prep-
aration of Defr1, antimicrobial activity was greatly reduced
(Fig. 2 and reference 3), indicating that a covalent dimeric
structure is necessary for the potent antimicrobial function
associated with the Defr1 sequence. This is supported by the
fact that the noncovalent dimer Defr1 Y5C with -defensin
connectivity displays poor antimicrobial activity even in the
oxidized form (3).
Studies of the relationship between the structure and func-
tion of defensins have begun to appear. For example, Pazgier
et al. (12) have shown that the antimicrobial activity of fully
oxidized -defensin HBD1 against E. coli is dominated by
cationic residues at the C terminus of the peptide. In an earlier
study, Wu et al. had demonstrated that a linear isomer of
HBD3 (where all the cysteines had been replaced with -ami-
nobutyric acid, so these residues of the isomer were unable to
form disulfide bonds) still retained its antimicrobial activity
against a panel of pathogens (18). Interestingly, de Leeuw et al.
reported that killing of E. coli by -defensin HD5 is indepen-
dent of the peptide structure whereas the activity against S.
FIG. 3. Gel electrophoresis of Defr1-1cys showing dimerization
and reduction (red) to a monomeric form with DTT. Unfractionated,
oxidized (ox) Defr1 and Defr1-1cys were analyzed on a Tricine gel
before and after reduction with 10 mM DTT.
FIG. 2. Antimicrobial activity before and after DTT treatment of
fractions 2, 9, and 13. The data represent the numbers of CFU of P.
aeruginosa PAO1 surviving after incubation with each of the three
reduced and unreduced Defr1 fractions at the concentrations shown.
All assays were performed in triplicate and were repeated on two
independent occasions.
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aureus is structure dependent (4). It appears that it is difficult
to explain the bactericidal properties of individual defensins
against specific pathogens solely based on their primary struc-
tures.
In the work presented here, the hypothesis that the antimi-
crobial activity of Defr1 appears to depend on covalent dimer-
ization of the molecule was confirmed by the activity of Defr1-
1cys. In this peptide, every cysteine except the penultimate one
is replaced with an alanine residue (Table 1). Importantly, this
molecule also forms a disulfide-linked dimer and displays very
similar antimicrobial activity, which is diminished in the re-
duced, monomeric from. A similar phenomenon was also ob-
served in the naturally-occurring Sushi 3 peptide derived from
the Sushi 3 domain of Factor C, the lipopolysaccharide-sensi-
tive serine protease of the horseshow crab coagulation cascade
(7). The antimicrobial peptides of the Sushi peptide (34 amino
acids, with a single cysteine) were shown to be due to its
interaction with lipopolysaccharide and correlated directly
with its ability to form a single S-S dimer.
Charge and hydrophobicity have been shown previously to
be important in the antimicrobial function of HBD3 deriva-
tives (5). However, the different antimicrobial activities of
Derf1 and Defr1-1cys versus Defr1 Y5C are not easily ex-
plained by simple differences in their physical properties, since
all three peptides have similar charge and hydrophobicity char-
acteristics (Table 1). The three peptides Defr1, Defr1 Y5C,
and Defr1-1cys have a cationic charge of 12 in the dimeric
form, and they share similar hydrophobic scores (1.92,
3.13, and 3.56 kcal mol1, respectively) on a scale which
measures the partitioning of peptides at a membrane to aque-
ous-phase interface. Common to Defr1 and Defr1-1cys and
absent in Defr1 Y5C is a covalent intermolecular S-S bond
which appears to be the governing factor in imparting potent
bactericidal activity for these peptides.
Synthetic peptides based on the Defr1 -defensin sequence
are antimicrobially potent even in the absence of the canonical
cysteine motif in a covalent, dimeric form. The mode of action,
toxicity, and in vivo efficacy of this naturally occurring murine
AMP remain to be determined. However, our results suggest
that further studies of these novel peptide antibiotics contain-
ing this simple S-S structural motif may provide a source of
optimized dimers capable of killing multiresistant pathogens.
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